Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AstraZeneca PLC - American Depositary Shares
(NQ:
AZN
)
90.18
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AstraZeneca PLC - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
↗
July 12, 2025
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at the catalysts that could be driving the attention.
Via
Benzinga
Why Is AbbVie Stock Trading Higher On Thursday?
↗
July 10, 2025
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.
Via
Benzinga
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
↗
July 09, 2025
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss.
Via
Benzinga
Topics
Intellectual Property
Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focus
↗
July 09, 2025
While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%.
Via
Stocktwits
Topics
ETFs
Government
Stocks
Price Over Earnings Overview: AstraZeneca
↗
July 02, 2025
Via
Benzinga
Artelo Biosciences Analyst See It As An Emerging Biotech
↗
July 08, 2025
Artelo gets Buy rating from Boral Capital after positive updates on ART27.13, ART26.12, and preclinical success of its candidate for depression.
Via
Benzinga
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
July 08, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MBIO),(NASDAQ:VSTM),(NASDAQ:CRDF),(NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
NIKE, Datadog And Snap Are Among Top 11 Large Cap Gainers Last Week (June 30-July 4): Are The Others In Your Portfolio?
↗
July 06, 2025
11 best performing large-cap stocks last week, including Symbotic, Nike, First Solar, Datadog, HPE, Summit Therapeutics, Carnival, POSCO, Wynn Resorts, SharkNinja, and Snap
Via
Benzinga
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
July 08, 2025
From
FN Media Group LLC
Via
GlobeNewswire
Why AstraZeneca Stock Got Thumped on Thursday
↗
July 03, 2025
Via
The Motley Fool
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
↗
July 03, 2025
Via
Benzinga
AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report
↗
July 03, 2025
While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, Bloomberg reported, while noting that...
Via
Stocktwits
Why AstraZeneca Stock Topped the Market on Tuesday
↗
July 01, 2025
Via
The Motley Fool
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
↗
June 30, 2025
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Via
Investor's Business Daily
3 No-Brainer Stocks to Buy for Under $100 Right Now
↗
June 28, 2025
Via
The Motley Fool
Topics
Intellectual Property
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.
↗
June 26, 2025
President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy.
Via
Investor's Business Daily
Topics
Government
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
June 24, 2025
From
AstraZeneca
Via
Business Wire
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer
↗
June 24, 2025
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.
Via
Benzinga
Is the Market Bullish or Bearish on AstraZeneca?
↗
June 20, 2025
Via
Benzinga
AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion
↗
June 13, 2025
AstraZeneca inks a multibillion-dollar deal with CSPC to co-develop AI-driven therapies for chronic and immune diseases, boosting its presence in China.
Via
Benzinga
AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer
↗
June 13, 2025
CSPC will receive an upfront payment of $110 million as part of the agreement, and is eligible to receive up to $1.62 billion in potential development milestone payments and up to $3.6 billion in sales...
Via
Stocktwits
Topics
Artificial Intelligence
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
↗
June 12, 2025
Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
June 12, 2025
Via
Benzinga
IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA
June 12, 2025
IonQ just hit investors with two pieces of big news. One shows proof of the company's tech being useful near-term. The other looks to aid its long-term goals.
Via
MarketBeat
Jensen Huang's Quantum Support Boosts IonQ's Growth Plans: Nvidia Partnership, Oxford Ionics Deal Lead Needham To Reiterate 'Buy'
↗
June 12, 2025
Needham maintained its 'buy' rating on IonQ, saying that the Oxford Ionics acquisition could propel 2 million physical qubits by 2030.
Via
Benzinga
What's Going On With IonQ Shares Monday?
↗
June 09, 2025
IonQ shares traded higher Monday after the company announced results of a collaborative research program with AstraZeneca, Amazon Web Services and Nvidia.
Via
Benzinga
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
↗
June 09, 2025
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.
Via
Benzinga
Is D-Wave Quantum a Better Quantum Computing Stock to Buy Than IonQ?
↗
June 09, 2025
Via
The Motley Fool
AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO
↗
June 02, 2025
AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ASCO 2025.
Via
Benzinga
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
↗
June 02, 2025
Three new cancer drugs could help make a dent in the company's ambitious plans for 2030.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
